Previous close | 399.75 |
Open | 399.75 |
Bid | 403.15 x 0 |
Ask | 403.40 x 0 |
Day's range | 399.75 - 399.75 |
52-week range | 276.50 - 400.85 |
Volume | |
Avg. volume | 1 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Transcendia Holdings, Inc. ("Transcendia" or the "Company"), a leader in manufacturing and converting custom engineered films, today announced it has entered into an agreement for a recapitalization transaction that will strengthen the Company's financial position and create a sustainable, long-term capital structure for the next phase of growth. The transaction will provide Transcendia with $114 million in new capital, eliminate more than $200 million of the Company's debt and further strengthe
Ms. Salka brings more than 30 years of healthcare leadership and staffing expertise, including strong C-suite, financial and ESG expertise to advance the company’s Patients-first focus and growth initiativesDURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Susan R. Salka, retired Chief Executive Officer and President
DirectBooks, a global leader in primary markets communications, announced today that Santander, Ramirez & Co. and Mischler Financial Group have joined the platform. The recent additions increase the number of underwriters participating on DirectBooks to 34 worldwide.